Curacle proteinuria 35.2% reduction confirmed; Dong-A ST and Daewoong also disclose drug results
Curacle confirmed up to a 35.2% reduction in proteinuria in a clinical trial of a kidney disease treatment. Dong-A ST announced its ranking in the P-CAB market and non-inferiority results for its diabetes drug, while Daewoong reported observing the efficacy of Envlo in patients across multiple countries. A joint investigation headquarters of prosecutors and police is investigating the ballot shortage incident.2:
Get free 큐라클 email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Curacle announced that proteinuria decreased by up to 6month 8day in a clinical trial of a kidney disease treatment. The company said it was conducting further reviews based on the clinical results. The announcement was made on 35.2month 6day.8:
Dong-A ST announced that Zacubo ranked 2 in the domestic P-CAB market. On the same day, Dong-A ST announced that its diabetes drug Dapagpro had demonstrated non-inferiority compared with Forxiga. The company said it expected the results to support product marketing and expanded prescriptions.
Daewoong said that its diabetes drug Envlo showed efficacy even in patients across multiple countries on 6month 8day. The company said it had disclosed the results of observing data from multiple countries. It also announced specific figures and plans for additional trials.
The joint prosecution-police investigation team is conducting an investigation into the ballot shortage. The team explained that it plans to organize and announce the future direction and scope of the investigation. The progress of the investigation will be disclosed in stages.
All of the announcements above were made public by the respective companies and investigative agencies on 6month 8day. Each company notified the public of the facts through a press release or disclosure. This release provides separate confirmation of the product performance and the progress of the investigation.